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Abstract
Background: Patients with primary oesophageal squamous cell carcinoma are at risk of developing multiple
primary tumours in the upper aero digestive tract. To date, most studies are performed in the Asian population.
We aimed to evaluate the risk of multiple primary tumours in the upper aero digestive tract and stomach in
patients with oesophageal squamous cell carcinoma in a Western population.
Methods: We performed a nationwide, retrospective cohort study in collaboration with the Netherlands Cancer
Registry. Patients with primary oesophageal squamous cell carcinoma, diagnosed between 2000–2016, were includ-
ed. Primary endpoints were synchronous and metachronous multiple primary tumour risk.
Results: The cohort consisted of 9058 patients, diagnosed with oesophageal squamous cell carcinoma (male:
57.3%, median age 67 years). In 476 patients (5.3%), 545 multiple primary tumours have been diagnosed. Most
of them were located in the head and neck region (49.5%). Among all multiple primary tumours, 329 (60.4%) were
diagnosed synchronously (<6 months after oesophageal squamous cell carcinoma diagnosis) and 216 (39.6%)
metachronously (6 months). Patients with oesophageal squamous cell carcinoma had a significantly increased
risk of both synchronous (standardised incidence ratio 10.95, 99% confidence interval 9.40–12.53) and metachro-
nous multiple primary tumours (standardised incidence ratio 4.36, 99% confidence interval 3.56–5.10), compared to
the general population. The median interval to metachronous second primary tumour diagnosis was 3.0 years
(interquartile range 1.8–5.9).
Conclusion: Approximately one in 20 patients with primary oesophageal squamous cell carcinoma have a second
primary tumour in the upper aero digestive tract or stomach, either at the time of oesophageal squamous cell
carcinoma diagnosis or at a later stage. As second primary tumours occur at an increased risk compared to the
general population, prospective studies are necessary to investigate the yield and survival benefit of screening for
second primary tumours in patients with oesophageal squamous cell carcinoma.
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• A minimum of one out of 20 patients with oesophageal squamous cell carcinoma (ESCC) in a Western
population develops multiple primary tumours (MPTs).
• Most MPTs were detected in the head and neck region, and were detected synchronously with a higher risk
than in the general population.
• Screening for both synchronous and metachronous MPTs in patients with primary ESCC should be
considered.
Introduction
Squamous cell carcinoma is the most common histo-
logic type of oesophageal cancer worldwide, and has
the highest incidence in Eastern Asia.1,2 Multiple pri-
mary tumours (MPTs) frequently develop in patients
with oesophageal squamous cell carcinoma (ESCC),
especially in the upper aero digestive tract (UADT).3,4
Since survival of patients with oesophageal cancer
has improved over the last years due to better treatment
options, the risk of developing MPTs may increase.5
These MPTs affect the prognosis and survival of
patients with ESCC, and the choice of ESCC treatment
in case of synchronous second primary tumour (SPT)
detection.6 It is therefore important to detect MPTs at
an early stage, when curative treatment is still possible.
The development of MPTs in the UADT particu-
larly occurs in patients with squamous cell carcinomas,
and can be explained by the ‘field cancerization’
theory.7 This theory states that premalignant epithelial
changes can occur around the primary tumour, due to
exposure to common carcinogens.7 Well-known carci-
nogens for the development of both ESCC and MPTs,
especially in the head and neck region and lungs, are
tobacco and alcohol.8,9
In retrospective studies, up to 19.3% of
patients with primary ESCC develop MPTs in the
UADT.3,10–13 Most studies consider the head and
neck region, lungs and oesophagus as the UADT, the
stomach is another important region to be at risk for
MPT development.3,12,14,15 Most studies about MPT
development, however, are performed in Asian popu-
lations. There is a lack of Western studies about MPT
incidence in ESCC patients.
We therefore conducted a nationwide, retrospective,
registry study of patients with primary ESCC to deter-
mine the risk of developing MPTs in the UADT and
stomach, in a Western country.
Materials and methods
Patient and study design
We conducted a nationwide, retrospective, registry
study in collaboration with the Netherlands Cancer
Registry (NCR; nationwide registry of all cancers).
Adult patients diagnosed with ESCC between 1
January 2000–31 December 2016 were selected from
the NCR. Patients were excluded when ESCC was
not the index tumour; defined as another tumour in
the UADT or stomach which was diagnosed >180
days prior to ESCC diagnosis. This study was
approved by the Medical Ethical Review Committee
of the Erasmus Medical Centre (MEC-2018-1631) on
7 January 2019. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki
as reflected in a priori approval by the institution’s
Human Research Committee.
Data collection
Anonymous patient data were obtained from the NCR.
The following data were available and collected: year
and age at ESCC diagnosis, sex, ESCC tumour char-
acteristics, the presence of metastases and ESCC treat-
ment. Tumour characteristics included histology,
location in the oesophagus (cervical part; <18 cm
from the incisors, upper third; 18–24 cm from the inci-
sors, middle third; 24–32 cm from the incisors, lower
third of the oesophagus; 32–40 cm from the incisors,
or overlapping locations; between two parts of the
oesophagus), differentiation grade, clinical and histo-
pathological Tumour, Node, Metastasis (TNM) stage
according to the 5th (2000–2002), 6th (2003–2009) and
7th (2010–2016) TNM stage classification.16–18 For
final analysis, we converted all different TNM classifi-
cations into the 7th TNM classification. cM1A classi-
fication was considered as M0 according to the 7th
TNM classification. Information about vital state
(alive or not) was collected until 31 January 2018.
We collected the following data of patients with
MPTs: MPT location in the UADT (defined as: head
and neck region, lungs and oesophagus) and in the
stomach, age at MPT diagnosis, year of MPT diagno-
sis, time between ESCC and MPT diagnosis, tumour
characteristics and MPT treatment. No information
was available about how MPTs were detected (e.g.
CT-scan, endoscopy). Diagnosis of MPTs was based
on information in medical records in accordance with
the Warren and Gates criteria: an MPT (a) must be
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malignant on histological examination, (b) must be
separated from the index tumour by normal mucosa,
and (c) may not be a metastasis of the index tumour.19
An MPT was defined as synchronous when it devel-
oped within 6 months before or after ESCC diagnosis,
and as metachronous when it developed 6 months
after ESCC diagnosis. This six month cut-off value
was used in most other studies about MPT develop-
ment in the UADT.20–22 Pathology information was
available in the NCR to verify that MPTs were not
metastases of the primary tumour. All MPTs were
identified, also whether patients had more primary
tumours (second, third etc.). The first MPT was also
called the SPT. During the study period of 16 years, no
MPT screening programmes were performed.
Study endpoints
The primary endpoint was the risk of MPTs in patients
with primary ESCC compared with the general popu-
lation. Secondary endpoints were; (a) MPT localization
in the UADT and stomach, (b) MPT histology, (c)
the proportion of synchronous and metachronous
MPTs, (d) the cumulative incidence of SPTs, (e) the
difference in survival between ESCC patients with
low (stage 0/I/II) and high (stage III/IV) stage meta-
chronous SPTs, and (f) risk factors associated with
MPT development.
Statistics
Continues variables were expressed as mean (stan-
dard deviation (SD)) and median (interquartile range
(IQR) and range) for normally and skewed distributed
variables, respectively. For risk factor analysis, a mul-
tivariate Cox proportional hazards model was used.
Hazard ratios (HRs) and 95% confidence intervals
(CIs) with a time-dependent covariate (follow-up time
until development of an SPT, death or the last date of
follow-up) were calculated in this model.
To assess the MPT risk in patients with primary
ESCC, the standardised incidence ratio (SIR) was cal-
culated with 99% CIs, assuming a Poisson probability
distribution for the occurrence of SPTs. The SIR was
defined as the total number of observed MPTs (the
study cohort) divided by the total number of expected
cancers in that same group of patients based on the
specific age, gender, year and type of cancer incidence
in general population. The SIR was calculated for dif-
ferent groups, separately for synchronous or metachro-
nous MPTs, and stratified in accordance with sex,
cancer location, age in 20 year intervals and cancer
treatment. Cancer incidence data from the general pop-
ulation were acquired from the NCR. The cumulative
incidence of SPTs was estimated with death as compet-
ing risk. STATA (v.14) was used for this analysis.
Survival analysis was determined by Kaplan-Meier
analysis, and we performed log-rank analysis using
SPSS. SIRs were calculated with SAS 9.2 software
(SAS Institute Inc., Cary, North Carolina, USA), all
other analyses were carried out using IBM SPSS ver-
sion 25. For SIRs, a two-sided test with a p-value of
<0.01 was considered significant. For all other analy-




We identified a total of 9810 patients with ESCC diag-
nosis between 1 January 2000–31 December 2016 in the
NCR. In total, 752 patients were excluded because
ESCC was not the index tumour (Figure 1). The
study cohort consisted of 9058 patients with primary
ESCC. The median age at ESCC diagnosis was 67
years (IQR 60–75), most patients were male (57.3%)
(baseline characteristics are shown in Table 1). The
total follow-up consisted of 17,072 person-years with
a median follow-up time of 9.8 months (IQR 4.2–23.8
months). The median survival after ESCC diagnosis
was 9.9 months (IQR 9.6–10.3). The overall five-year
survival rate of the total cohort was 15.9%.
ESCC characteristics
The majority of ESCCs were located in the middle
(36.4%) and lower third (38.7%) of the oesophagus
(Table 1). ESCC tumour stage was low in 26.3% and
high in 55.7% of patients. Pathological assessment of
ESCCs revealed good or moderate differentiation
grade (G1/G2) in 33.5%, and poor or undifferentiated
grade (G3/G4) in 28.7%. In total, 2372 patients
(26.2%) had distant metastases at time of diagnosis
(cM stage). In total, 2163 patients (23.9%) were treated
with radiotherapy for ESCC, 1812 patients (20.0%)
with chemo-radiotherapy and 1288 (14.2%) patients
received neoadjuvant therapy followed by surgery.
MPTs
A total of 545 MPTs were registered in 476 (5.3%)
patients. Of these 476 patients, 50 patients developed
a third primary tumour, 16 patients a fourth primary
tumour, and one patient developed another fifth, sixth
and seventh primary tumour (Figure 1). Of all MPTs
(545), 329 (60.4%) were diagnosed synchronously and
216 (39.6%) metachronously (Table 2). The majority of
both synchronous and metachronous MPTs were
located in the head and neck region (270/545; 49.5%)
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and lungs (219/545; 40.2%). MPT tumour stage was
low (stage 0/I/II) in 39.6%, and high (stage III/IV) in
43.5% of the tumours, which was roughly the same for
synchronous and metachronous MPTs. Of all MPTs,
160/545 (29.4%) were treated with radiotherapy and
170/545 MPTs (31.2%) did not receive any treatment.
Squamous cell carcinoma (337/545; 61.8%) was the
most prevalent histologic MPT type (Table 2).
SIRs
In total, 545 MPTs were detected during the observa-
tion period. Patients with ESCC had a significantly
increased risk of both synchronous (SIR 10.95, 99%
CI 9.40–12.53) and metachronous MPTs (SIR 4.36,
99% CI 3.56–5.10) compared to the general population
(Table 3). Sub-analyses showed that patients with
ESCC had the highest risk of developing synchronous
(SIR 36.33, 99% CI 29.44–44.30) and metachronous
(SIR 14.17, 99% CI 10.41–17.52) MPTs in the head
and neck region. Patients aged 41–60 years at ESCC
diagnosis had a highest SIR of 32.07 (99% CI 24.71–
40.77) for developing synchronous MPTs, and patients
aged 18–40 years at ESCC diagnosis had a highest SIR
of 70.87 (99% CI 2.72–329.97) for developing
metachronous MPTs. In order to determine whether
radiotherapy had influence on MPT development com-
pared to other treatments, we stratified the MPT risk
for different treatment groups. The MPT risk was high
for all different treatment groups compared to the gen-
eral population. We were unable to address any influ-
ence of previous radiotherapy on MPT development; of
patients who developed metachronous MPTs >10
years after ESCC diagnosis (n¼ 15), only four patients
received radiotherapy for ESCCs. For all sub-analyses,
females had the highest SIR compared to males
(Table 3).
Metachronous SPT
Of all patients who were alive 6 months after ESCC
diagnosis (n¼ 5715), 191 patients developed metachro-
nous MPTs. Of these patients, 16 had already devel-
oped a synchronous SPT. In total, 175 patients
developed a metachronous SPT. Figure 2 shows the
cumulative incidence of metachronous SPTs. Fifteen
years after ESCC diagnosis, the cumulative incidence
of metachronous SPTs was 19.7%. Cumulative inci-
dences of different SPT sub-locations is shown in the
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Figure 1. Flow-chart patient selection and multiple primary tumour (MPT) development. ESCC: oesophageal squamous cell
carcinoma; HN: head and neck; SPT: second primary tumour; UADT: upper aero digestive tract.
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and S2. The median time between ESCC diagnosis and
metachronous SPT diagnosis was 3.0 years (IQR 1.8–
5.9). The median time between ESCC and metachro-
nous head and neck SPT diagnosis was 2.8 years (IQR
2.2–3.4) and for lung SPT diagnosis 3.2 years (IQR
1.9–4.5). SPT stage was high (stage III/IV) in 57.4%
of the patients with metachronous SPTs. These patients
had a significantly worse two-year survival after SPT
diagnosis than low stage SPTs (stage 0/I/II) (15.1% vs
51.9%, p< 0.01) (Figure 3).
Cumulative incidence of MPTs in patients
with low-stage ESCC
Subgroup analysis was performed in patients with low-
stage ESCC (n¼ 2381). The 15-year cumulative





Median age (years) (IQR) 67 (60–75)
Follow-up
Person-years at risk (years) 17,072
Median follow-up (months) (IQR) 9.8 (4.2–23.8)
Vital status (31-01-2018), n (%)
Alive 1358 (15.0%)
Dead 7700 (85.0%)
Overall survival after ESCC diagnosis (months)
Median survival (95% CI) 9.9 (9.6–10.3)
Anatomical sub-location, n (%)
Cervical oesophagus 276 (3.0%)
Upper third oesophagus 1236 (13.6%)
Middle third oesophagus 3301 (36.4%)
Lower third oesophagus 3501 (38.7%)
Oesophagus overlapping or unspecified 744 (8.3%)







Differentiation grade, n (%)
Grade 1 (good) 298 (3.3%)
Grade 2 (moderate) 2,739 (30.2%)
Grade 3 (poor) 2,594 (28.6%)
Grade 4 (undifferentiated) 8 (0.1%)
Missing 3419 (37.8%)
Distant metastases at diagnosis (cM stage), n (%) 2372 (26.2%)
ESCC treatment, n (%)
Endoscopic resection 116 (1.3%)
Surgical resection 734 (8.1%)
Chemotherapy 479 (5.3%)
Radiotherapy 2163 (23.9%)
Chemotherapyþ radiotherapy 1812 (20.0%)
neoadjuvant chemotherapyþ surgery 267 (2.9%)
Chemotherapy þradiotherapyþ surgery 1021 (11.3%)
Surgeryþ radiotherapy 25 (0.3%)
Othera 61 (0.7%)
No therapy 2380 (26.2%)
CI: confidence interval; IQR: interquartile range.
aOther treatment combinations with either endoscopic or surgical resection combined with (neo)adjuvant
chemo and/or radiotherapy.
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incidence for this subgroup was 21.7% (Supplementary
Material Table S5 and Figure S3).
Predictive factors for MPTs
Multivariable Cox proportional hazard analysis
showed that being male (HR 1.59, 95% CI 1.29–1.97,
p< 0.001), age <70 years (HR 1.51, 95% CI 1.19–1.90,
p¼ 0.001), and having a low ESCC tumour stage (stage
0/I/II) at diagnosis (HR 1.50, 95% CI 1.19–1.89,
p¼ 0.001) were independent predictors for MPT devel-
opment (Table 4). Analysis with age (HR 0.99, 95% CI
0.98–0.10, p¼ 0.022) and tumour stage (HR 0.73, 95%
CI 0.64–0.82, p<0.001) as continues variables did not
alter the outcomes.
Discussion
We determined the risk of developing MPTs in the
UADT and stomach in patients with primary ESCC.
Our study shows that a minimum of one out of 20
patients with primary ESCC develops an SPT, with a
15-year cumulative metachronous SPT incidence of
19.7%. Which means that approximately one in five
ESCC patients who survive longer than 6 months will
develop an SPT within 15 years. The risk of developing
synchronous (SIR 10.95) and metachronous MPTs
(SIR 4.36) among patients with primary ESCC was
increased compared to the general population, with
the highest risk of developing MPTs in the head and
neck region. Risk factors associated with MPT devel-
opment are being male, age <70 years and low ESCC
tumour stage.
In retrospective studies, the incidence of MPTs
localised the UADT among patients with primary
ESCC ranged between 1.9–19.3%.3,10–13 Most studies
are performed in the Asian population, where the MPT
incidence is reported to be >10%.3,11,13,23 Studies per-
formed in a Western population reported lower MPT
incidences (1.9–6.3%), which is in accordance with our
findings.12,24,25 The difference in MPT incidence
between Asian and non-Asian populations could pos-
sibly be explained by a difference in aetiology. While
the aetiology of ESCC and MPTs in the UADT is
clearly linked to smoking and alcohol intake in a
Western population, the aetiology in an Asian popula-
tion is also linked to a poor nutritional status.26,27
Table 2. Tumour characteristics of all multiple primary tumours (MPTs) (545).
Characteristics Total (545) Synchronous (329) Metachronous (216)
MPT location, n (%)
Head and neck region 270 (49.5%) 167 103
Lung 219 (40.2%) 123 96
Oesophagus 26 (4.8%) 14 12
Stomach 30 (5.5%) 25 5
Histology, n (%)
Squamous cell carcinoma 337 (61.8%) 196 141
Adenocarcinoma 79 (14.5%) 50 29
Carcinoid 2 (0.4%) 2 0
Neoplasm and carcinoma (unspecified) 127 (23.3%) 81 46
Tumour stage, n (%)
0 11 (2.4%) 6 5
1 149 (32.9%) 86 63
2 56 (12.4%) 37 19
3 65 (14.3%) 38 27
4 172 (38.0%) 94 78
Missing 92 68 24
MPT treatment , n (%)
Endoscopic resection 20 (3.7%) 8 12
Surgical resection 60 (11.0%) 32 28
Chemotherapy 45 (8.3%) 22 23
Radiotherapy 160 (29.4%) 90 70
Chemotherapyþ radiotherapy 72 (13.2%) 54 18
Chemoþ surgery 1 (0.2%) 1 0
Chemoþ radioþ surgery 2 (0.4%) 2 0
Surgeryþ radio 13 (2.4%) 5 8
Surgeryþ chemoþ radio 1 (0.2%) 1 0
Endoscopic resectionþ radio 1 (0.2%) 0 1
No treatment 170 (31.2%) 114 56
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Another explanation might be the difference in genetic
polymorphisms in alcohol metabolism between Asian
and Western populations.28,29
The increased MPT risk among patients with prima-
ry ESCC, as reported in our study, has also been
reported in other studies.12,15,30,31 Chuang et al.
reported an increased risk of MPTs in the UADT,
especially in the head and neck region (SIR 6.68) and
lungs (SIR 1.55), among ESCC patients in 13 different
countries.15 Other studies also reported increased MPT
risks.10,14,24,30,32 As reported in our study, patients with
ESCC diagnosis at a young age showed the highest SIR
for developing both synchronous (SIR 32.07) and
metachronous MPTs (SIR 70.87). The same results
were reported in a study by Chen et al., with a SIR
of 36.56 for patients aged between 20–39 years at
ESCC diagnosis.30
We found the head and neck region to be the most
common region for developing MPTs (synchronous;
SIR 36.33, metachronous: SIR 14.17), which is also
reported in both Asian (SIR 15.83) and Western (SIR
6.68–8.64) studies.12,14,15,30,31 Studies from Japan and
Korea reported the stomach as their most common
MPT location.3,4 This could be due to the high inci-
dence of stomach cancer in Japan and Korea.2
Unfortunately, SIRs were not reported in these stud-
ies.3,4 For synchronous MPTs, we found the stomach
to be the second most common region for MPT devel-
opment. Less patients had synchronous or metachro-
nous oesophageal MPT in our cohort. In case a
synchronous oesophageal SPT is detected, one could
argue that these patients probably had mucosal dyspla-
sia or neoplasia at the time of the primary ESCC diag-
nosis. Careful inspection of the oesophagus with Lugol
chromoendoscopy is therefore very important in cases
of curative primary ESCC diagnosis, because early
oesophageal SPT might be easily overlooked during
routine white light endoscopy.33













All cancers 329 30.05 10.95 (9.40–12.53) 9.82 (8.20–11.65) 14.07 (10.79–17.98)
Head and neck 164 4.51 36.33 (29.44–44.30) 34.69 (27.05–43.76) 41.51 (27.29–60.29)
Lungs 123 19.17 6.42 (5.02–8.06) 5.35 (3.90–7.14) 9.48 (6.29–13.66)
Stomach 25 3.16 7.92 (4.43–12.99) 7.75 (3.84013.83) 8.37 (2.40–20.52)
Oesophagus 17 4.04 4.21 (2.04–7.63) 3.14 (1.00–7.30) 10.64 (3.05–26.08)
Age at ESCC diagnosis (years)
41–60 110 3.43 32.07 (24.71–40.77) 28.26 (20.21–38.35) 40.86 (26.43–60.09)
61–80 202 22.57 8.95 (7.41–10.70) 8.15 (6.49–10.09) 11.56 (8.10–15.95)
>80 17 4.04 4.21 (2.04–7.63) 4.99 (2.21–9.56) 2.44 (0.25–8.96)
Treatment ESCC
Chemoþ radiotherapy 100 9.85 10.15 (7.73–13.08) 9.25 (6.58–12.61) 12.53 (7.68–19.21)
Chemotherapy 22 2.15 10.23 (5.47–17.31) 7.99 (3.54–15.32) 20.09 (6.39–46.71)
Radiotherapy 88 8.59 10.24 (7.75–13.55) 9.49 (6.69–13.03) 13.34 (7.56–21.69)
No chemo- or radiotherapy 119 9.48 12.60 (9.98–16.08) 11.72 (8.65–15.48) 15.74 (10.00–23.48)
Metachronous MPTs
All cancers 216 49.51 4.36 (3.56–5.10) 3.84 (3.03–4.79) 5.25 (3.87–6.93)
Head and neck 106 7.48 14.17 (10.41–17.52) 12.85 (9.19–17.44) 15.55 (9.53–23.85)
Lungs 96 31.95 3.00 (2.22–3.82) 2.50 (1.71–3.53) 3.81 (2.45–5.62)
Stomach 5 4.56 1.10 (0.23–3.11) 0.94 (0.10–3.46) 1.45 (0.06–6.76)
Oesophagus 9 5.53 1.63 (0.78–4.12) 1.42 (0.36–3.70) 3.86 (0.81–10.95)
Age at ESCC diagnosis (years)
18–40 2 0.03 70.87 (2.72–329–97) 157.62 (6.05–733.84) 0.00
41–60 95 11.02 8.62 (6.35–10.96) 6.94 (4.65–9.93) 11.10 (7.26–16.18)
61–80 115 36.17 3.18 (2.42–3.96) 2.99 (2.18–4.00) 3.44 (2.15–5.18)
>80 4 2.30 1.74 (0.28–5.50) 2.12 (0.22–7.79) 1.13 (0.00–8.46)
Treatment ESCC
Chemoþ radiotherapy 112 24.89 4.50 (3.44–5.67) 3.87 (2.77–5.25) 5.88 (3.82–8.61)
Chemotherapy 19 6.05 3.14 (1.47–5.31) 2.87 (1.22–5.62) 3.30 (0.69–9.36)
Radiotherapy 26 5.68 4.58 (2.46–7.22) 3.58 (1.59–6.88) 6.18 (2.42–12.82)
No chemo- or radiotherapy 59 12.89 4.58 (3.12–6.26) 4.45 (2.75–6.78) 4.58 (2.49–7.67)
CI: confidence interval.
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Patients who develop metachronous SPT may
potentially benefit from screening programmes. The
median time between ESCC diagnosis and metachro-
nous SPT detection was 3 years (IQR 1.8–5.9 years),
with a cumulative 15-year incidence of 19.7%. Most
metachronous SPTs, however, had a high tumour
stage (57.4%), with a worse two-year survival com-
pared to low-stage metachronous SPTs (15.1% versus
51.9%, p<0.01). Screening for metachronous SPTs
could possibly help to increase survival in these patients
by detecting these SPTs at an early stage. Patients with
high-stage ESCC with poor prognosis will possibly not
benefit from screening programmes since their progno-
sis is already determined by the ESCC. Diagnosing
MPTs in these patients is probably not clinically rele-
vant. The overall survival of our cohort was 9.9
months, the overall five-year survival was 15.9%.
Prospective studies are necessary to investigate the
yield of screening for MPTs, and especially whether
screening will lead to survival benefit. One could
argue that synchronous SPTs already existed at time
of index tumour diagnosis but had not yet been
detected at that time. The question arises whether rou-
tine screening of especially the head and neck region
should be performed in curative ESCC patients prior to
ESCC treatment.
Asian screening studies to detect head and neck
SPTs have been performed in patients with primary
ESCC. A systematic review about active screening for
head and neck SPTs in patients with primary ESCC
showed a pooled prevalence of 6.7% (range 3.0–
29.6%).22 Active screening showed a low SPT tumour
stage in most patients (85.7%), and a better survival
compared to patients who were not screened.22,34 These
studies suggest that active screening contributes to an
increase in SPT detection and overall survival.4
Nowadays, no screening studies in patients with
ESCC have been performed in Western countries.
Being male was a predictive factor for MPT devel-
opment in our study, which is in accordance with pre-
vious studies.24,30,31 Our study revealed age <70 years
as a significant predictive factor, which is also in line
with a previous study.24 Chen et al., however, reported
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Figure 2. Cumulative incidence of metachronous second primary tumour (SPT) after oesophageal squamous cell carcinoma
(ESCC) diagnosis. Censored cases: patients in column ‘death (n)’, Number at risk: patients in column ‘Begin total (n)’. CI:
confidence interval.
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development.30 Although higher age is reported as a
significant risk factor for cancer development in the
UADT or stomach in general, one might hypothesise
that when patients survive ESCC at a young age they
are expected to live longer and might have an increased
risk of MPT development. The same might be true for
patients with a low ESCC tumour stage, they have a
more favourable course of their disease and are there-
fore expected to live longer. We reported low ESCC
tumour stage as a predictive factor for MPT develop-
ment, but this has to be interpreted with caution.
Although this is the largest registry study in Europe
with more than 9000 patients, some limitations need to
be acknowledged. First, this is a retrospective cohort
study with limited patient information and a substan-
tial amount of missing data. We could therefore not
report on risk factors such as smoking or alcohol
which are common risk factors for MPT
1.0
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Low stage (0-II) or  high stage (III-IV) metachronous SPT
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Figure 3. Survival after second primary tumour (SPT) diagnosis between low- and high-stage metachronous SPTs. *n¼155; 21
patients were excluded for this analysis, as result of missing SPT tumour stages.
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development.30 This might have caused confounding in
our risk factor analysis. In addition, cause of death was
not reported in the NCR and this information could be
relevant in this patient cohort with a large number of
high-stage ESCCs and a median survival of only 10
months. Second, since this is a registry study, MPT
incidence could be underestimated. Because of the ret-
rospective design of this study, we did not know wheth-
er MPTs were diagnosed during regular follow-up or as
a result of patients symptoms. As a consequence, no
specific advice for time interval for screening can be
drawn from this study.
A minimum of one out of 20 patients with primary
ESCC develops an MPT in the UADT or stomach. The
majority of these MPTs were detected synchronously,
in the head and neck region and in young patients.
Survival of patients with ESCC is low. Prospective
screening studies are necessary to determine the true
MPT incidence and to investigate the yield and benefit
of screening for MPTs.
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